ADRM1 and Miyoshi myopathy: To test whether hRpn13 is required for XL5-VHL-2 cellular toxicity, we compared the effect of XL5-VHL-2 treatment for RPMI 8226 WT cells versus the two trRpn13-MM cell lines.